
KEY PRODUCTS
KEY SERVICES
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Lead Product(s) : RVU120
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Ryvu Therapeutics
Deal Size : $1.9 million
Deal Type : Agreement
Ryvu Therapeutics Signs Agreements with Polpharma for RVU120 API Production
Details : The agreement will support the clinical development of RVU120, a miscellaneous product targeting CDK8, to address Acute Myeloid Leukemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 06, 2023
Lead Product(s) : RVU120
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Ryvu Therapeutics
Deal Size : $1.9 million
Deal Type : Agreement
Lead Product(s) : Marimastat
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Pikralida
Deal Size : Undisclosed
Deal Type : Partnership
Polpharma Partners with Pikralida Biopharmaceutical Startup
Details : The partnership with Marimastat aims to advance epilepsy treatment by targeting MMP.
Product Name : PKL-021
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 19, 2022
Lead Product(s) : Marimastat
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Pikralida
Deal Size : Undisclosed
Deal Type : Partnership



European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.